

The role of prison-based interventions for hepatitis C virus (HCV)
micro-elimination among people who inject drugs in Montréal, Canada:
Supplementary material S2

Table S2.1: Posterior distribution of model parameters.

Parameter	Symbol	Median	95%CrI	Units
<i>HCV transmission</i>				
Transmission rate	β	0.44	0.37 – 0.53	per PY
Degree of assortative mixing				
Incarceration	mix_p	0.41	0.02 – 0.96	-
Injection status	mix_i	0.55	0.05 – 0.97	-
Recruitment rate	θ	298	192 – 346	people per year
Fibrosis progression rate	ξ	0.027	0.025 – 0.029	metavir units/year
HCV Testing rate	$\tau(t)$	25.1	10.9 – 39.3	per 100 PY
Rate ratio for HCV risk [‡] on OAT	rr_{oat}	0.50	0.43 – 0.58	-
Rate ratio for HCV risk [‡] among releasees	Γ	1.59	1.27 – 2.02	-
Rate ratio for mortality among releasees	Π	7.42	5.70 – 9.94	-
<i>Incarceration dynamics</i>				
Incarceration rate [†]				
2003	$\eta_0(2003)$	11.5	10.7 – 12.4	per 100 PY
Release rate [†]				
2003	$\eta_1(2003)$	779	703 – 847	per 100 PY
<i>Injection dynamics</i>				
Injection cessation rate	$\frac{1}{\delta_0}$	0.055	0.044 – 0.075	per year

* HCV: hepatitis C virus, OAT: opioid agonist therapy, PY: Person-Year.

† Only the posterior for 2003 was shown for these two quantities. Similar distributions were observed over the years.

‡ Risk of HCV acquisition and transmission.

Table S2.2: Epidemiological impact of different prison-based interventions scenarios in terms of relative reduction in prevalence, incidence, and fraction of chronic HCV infections prevented between 2018 and 2030, as compared to a status quo and a community treatment scale-up scenarios.

Scenario	Relative reduction in prevalence	Relative reduction in incidence	Prevented fraction
	%(95%CrI) [‡]	%(95%CrI)	%(95%CrI)
<i>Status quo</i>			
Test and treat (PB T-Tx)	27 (20–34)	19 (9–28)	7 (4–10)
Test and linkage to care (PB T-L)	30 (22–38)	23 (11–33)	9 (5–14)
PB T-Tx + Post-release risk reduction	32 (25–41)	30 (17–41)	10 (6–17)
PB T-L + Post-release risk reduction	36 (28–45)	33 (20–45)	13 (7–20)
<i>Community scale up of DAA</i>			
Test and treat (PB T-Tx)	58 (45–71)	47 (27–62)	14 (7–20)
Test and linkage to care (PB T-L)	67 (53–78)	57 (36–70)	19 (11–27)
PB T-Tx + Post-release risk reduction	68 (53–81)	62 (43–78)	21 (12–32)
PB T-L + Post-release risk reduction	75 (61–85)	69 (50–83)	26 (13–36)

‡ Numbers in parenthesis represent 95% credible interval




Figure S2.1: Fibrosis levels among all PWID from 2003 to 2030 under (top) the status quo, and (bottom) a community-based DAA scale-up. Where *PB T-Tx* is a test-and-treat intervention in which 90% are tested and 75% of chronic cases are treated while in prison; *PB T-L* is a post-release linkage to care intervention where 90% of people are tested in prison and 75% are treated upon release; *PB T-Tx + Risk* or *PB T-L + Risk* are the same interventions where the elevated post-release risk is halved.




Figure S2.2: Knowledge of HCV status among all PWID from 2003 to 2030 under (top) the status quo, and (bottom) a community-based DAA scale-up. Where *PB T-Tx* is a test-and-treat intervention in which 90% are tested and 75% of chronic cases are treated while in prison; *PB T-L* is a post-release linkage to care intervention where 90% of people are tested in prison and 75% are treated upon release; *PB T-Tx + Risk* or *PB T-L + Risk* are the same interventions where the elevated post-release risk is halved. The data points represent empirical estimates of HCV status among community PWID with 95% confidence interval.